New project: Circulating tumour DNA technology use in cancer management
Could circulating tumour DNA (ctDNA) technologies be the future of cancer management? We have launched a new project to investigate and to ensure future services are implemented effectively and efficiently.
Precision diagnosis in ovarian cancer
A report on the findings of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) research study and the implementation of the NHS GTEOC service within the East Anglia region has been produced by Cambridge University Hospitals NHS Foundation Trust and PHG Foundation. The GTEOC study found a novel approach to testing BRCA1 or BRCA2 mutations in woman with ovarian cancer in East Anglia could increase precision diagnosis and enable more targeted treatments for patients or risk-reducing options in unaffected family members. The new report highlights the benefits of the GTEOC approach for other service providers who may consider implementing this within their own region.
Improving access to genetic testing in epithelial ovarian cancer
Study offers new pathway to increase precision diagnosis in ovarian cancer
Rare disease strategy
Following APPG on Rare, Genetic and Undiagnosed conditions launching an inquiry into why the Department of England has not yet developed or coordinated a plan for the commitments outlined in the UK strategy for Rare Diseases, we give our thoughts and think NHS England approach is coming up short.
Leila Luheshi considers whether this could be the year that ‘patient benefits from genomic medicine’ is no longer newsworthy and becomes just business as normal. In the news, a new collaborative study identifies rare mutations and disease causing genetic variants through the linkage of sequencing data from participants and their electronic health records, and a new global partnership has received a cash injection of 15 million Euros from the Eu ropean Commission to enable more personalised therapies in multiple sclerosis.
Researchers at the Scripps Institute California have created semi-synthetic bacteria by adding new synthetic base pairs into its DNA. In microbiome news, a team from Washington say they have developed a system that aims to characterise and quantify changes in the microbiome and how they might link to disease, while the Wellcome Trust Sanger Institute has announced the formation of a new company, Microbiotica Ltd, which aims to commercialise bacteriotherapies.